/stocks — the workspaceLOADING
Vaxcyte, Inc. (PCVX) is a biological products, (no diagnostic substances) company. 16 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-05 from PCVX's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Not reported in XBRL for this filer.
A plain-English read on PCVX plus an auto-SWOT — built from PCVX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate PCVX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Gilbert CisnerosU.S. Representative · CA-39 | BUY | $1,001 - $15,000 | filed 2026-06-08 |
| Gilbert CisnerosU.S. Representative · CA-39 | BUY | $1,001 - $15,000 | filed 2026-06-08 |
| Baupost Group (Seth Klarman) | $46K | 0.9% of portfolio |
Projected from PCVX's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment PCVX files its announcement.
PCVX has sold off after 6 of its last 8 earnings reports.
Earnings reactions have been moderate.
PCVX has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+7.6% and -11.0%).
A more typical earnings reaction has been approximately ±5.2%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-05-06 | -7.5% |
| 2026-02-24 | +4.6% |
| 2025-11-04 | -5.9% |
| 2025-08-06 | -11.0% |
| 2025-05-07 | +7.6% |
| 2025-02-25 | -3.7% |
| 2024-11-05 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -2.3% |
| 2024-08-06 | -3.1% |
| Wassil JimCHIEF OPERATING OFFICER | SELL | $127K | view → |
| GUGGENHIME ANDREWPRESIDENT AND CFO | SELL | $573K | view → |
| PICKERING GRANTCHIEF EXECUTIVE OFFICER | SELL | $1.3M | view → |
| GUGGENHIME ANDREWPRESIDENT AND CFO | SELL | $530K | view → |
| PICKERING GRANTCHIEF EXECUTIVE OFFICER | SELL | $1.3M | view → |
| Wassil JimCHIEF OPERATING OFFICER | SELL | $111K | view → |
| Wassil JimCHIEF OPERATING OFFICER | SELL | $128K | view → |
| Cowan ElviaSVP, Finance & CAO | SELL | $180K | view → |